Effect of Bilateral Greater Occipital Nerve Block on Headache After Intracranial Aneurysm Coiling
Effect of Preoperative Ultrasound-Guided Bilateral Greater Occipital Nerve Block on Postoperative Headache Following Endovascular Coiling of Unruptured Intracranial Aneurysms: A Prospective, Randomized, Sham-Controlled Trial
Postoperative headache is a common complication following endovascular coil embolization of intracranial aneurysms and may increase analgesic requirements, impair patient comfort, and contribute to hemodynamic instability.
The greater occipital nerve (GON) has anatomical and functional connections with the trigeminocervical complex, suggesting that greater occipital nerve blockade may modulate headache-related pain pathways. However, the effectiveness of prophylactic greater occipital nerve block in patients undergoing elective endovascular coiling of unruptured intracranial aneurysms remains uncertain.
This prospective, randomized, sham-controlled, single-center clinical trial aims to investigate whether preoperative ultrasound-guided bilateral greater occipital nerve block reduces postoperative headache intensity during the first 24 hours following endovascular coil embolization.
A total of 76 patients will be randomly allocated in a 1:1 ratio to receive either ultrasound-guided bilateral greater occipital nerve block with 0.25% bupivacaine or bilateral superficial sham injections with 0.9% normal saline.
The active intervention will consist of 3 mL of 0.25% bupivacaine administered on each side in the fascial plane between the semispinalis capitis and obliquus capitis inferior muscles. The control intervention will consist of a superficial subcutaneous injection of 0.5 mL of 0.9% normal saline on each side.
All participants will receive standardized general anesthesia and postoperative multimodal analgesia.
The primary outcome will be the time-weighted average resting pain score during the first 24 postoperative hours, calculated from the area under the Numeric Rating Scale (NRS) pain score-time curve.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Ömer Keklicek, Principal Investigator
- Telefoonnummer: +905399291702
- E-mail: drokeklicek@gmail.com
Studie Locaties
-
-
Konya
-
Konya, Konya, Turkije (Türkiye), 42090
- Werving
- Konya City Hospital
-
Contact:
- Ömer Keklicek
- Telefoonnummer: +905399291702
- E-mail: drkeklicek@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients aged 18-65 years.
- American Society of Anesthesiologists (ASA) physical status I-III.
- Patients scheduled for elective endovascular coil embolization of a unilateral unruptured intracranial aneurysm under general anesthesia.
- Ability and willingness to provide written informed consent.
Exclusion Criteria:
- Refusal to provide informed consent or subsequent withdrawal of consent.
- Ruptured intracranial aneurysm or acute subarachnoid hemorrhage requiring emergency intervention.
- Clinical contraindications to greater occipital nerve block, including infection or skin lesions at the injection site, local anesthetic allergy, or anatomical conditions preventing safe needle placement.
- Platelet count below 100,000/mm³, international normalized ratio (INR) greater than 1.5, activated partial thromboplastin time (aPTT) greater than 1.5 times normal, or clinically significant coagulopathy.
- Antithrombotic or antiplatelet treatment that does not meet the predefined safety intervals for deep peripheral nerve blocks according to the ASRA 2025 and ESAIC/ESRA guidelines.
- Moderate-to-severe preoperative headache, defined as a resting Numeric Rating Scale score of 3 or higher.
- Known history of severe hypersensitivity or allergic reactions to local anesthetics.
- Chronic opioid use, chronic pain syndrome, or regular analgesic use that may substantially interfere with postoperative pain assessment.
- Uncontrolled hypertension or clinically significant uncontrolled cardiac arrhythmia.
- Pregnancy or breastfeeding.
- Neurological deficits, aphasia, impaired consciousness, cognitive impairment, or communication difficulties preventing reliable pain assessment using the Numeric Rating Scale.
- Body mass index greater than 35 kg/m².
- Clinical circumstances requiring initiation of intravenous unfractionated heparin within one hour after the planned study-related needle intervention.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Postoperative headache is a common complication following endovascular coil embolization of intracra
Participants assigned to the experimental group will receive preoperative ultrasound-guided bilateral greater occipital nerve block with 0.25% bupivacaine before induction of general anesthesia. A total of 3 mL of 0.25% bupivacaine (7.5 mg) will be administered on each side into the interfascial plane between the semispinalis capitis and obliquus capitis inferior muscles. The total bilateral dose will be 15 mg of bupivacaine in 6 mL. The intervention will be performed while the patient is awake and able to communicate, without routine deep sedation. All participants will subsequently receive standardized general anesthesia and postoperative multimodal analgesia. |
Ultrasound-guided bilateral greater occipital nerve block will be performed before general anesthesia induction using a high-frequency linear ultrasound transducer. The greater occipital nerve will be identified between the semispinalis capitis and obliquus capitis inferior muscles. A 25-gauge, 50-mm echogenic needle will be advanced under continuous ultrasound guidance using an in-plane approach. Following color Doppler assessment and negative aspiration, 3 mL of 0.25% bupivacaine (7.5 mg) will be injected slowly and incrementally on each side. The total bilateral dose will be 15 mg of bupivacaine. |
|
Sham-vergelijker: Bilateral Superficial Sham Injection
Participants assigned to the control group will receive bilateral superficial subcutaneous sham injections with 0.9% normal saline before induction of general anesthesia. Following the same general preparation, positioning, and ultrasound examination as the experimental group, 0.5 mL of 0.9% normal saline will be injected subcutaneously on each side of the occipital region using a short 27-gauge needle. The total bilateral injection volume will be 1 mL. The needle will not be advanced into the deep interfascial plane, and no injection will be performed around the greater occipital nerve. All participants will receive standardized general anesthesia and postoperative multimodal analgesia. |
A bilateral superficial subcutaneous sham injection will be performed before general anesthesia induction. Following standardized positioning, skin antisepsis, and ultrasound examination, a short 27-gauge needle will be used to administer 0.5 mL of 0.9% normal saline subcutaneously on each side of the occipital region. The total bilateral injection volume will be 1 mL. The needle will not be advanced into the deep interfascial plane, and the greater occipital nerve will not be directly targeted. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time-Weighted Average Resting Pain Score During the First 24 Postoperative Hours
Tijdsspanne: From postoperative hour 0 to postoperative hour 24
|
Postoperative resting pain intensity will be assessed using the 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). NRS scores will be recorded at postoperative hours 0, 2, 4, 6, 8, 12, and 24. The area under the NRS pain score-time curve (AUC0-24) will be calculated using the linear trapezoidal method and divided by 24 hours to obtain the time-weighted average NRS score. The resulting patient-level value will range from 0 to 10, with higher scores indicating greater overall postoperative pain intensity. |
From postoperative hour 0 to postoperative hour 24
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pijn
- Neurologische manifestaties
- Cerebrovasculaire aandoeningen
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Vaatziekten
- Hart-en vaatziekten
- Postoperatieve complicaties
- Pathologische processen
- Intracraniële arteriële aandoeningen
- Aneurysma
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Pijn, postoperatief
- Intracraniaal aneurysma
Andere studie-ID-nummers
Andere studie-ID-nummers
- 2026_KAEK-64_28
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .